@DavidSantoro1 @DrEricDing @HelenBranswell @drdianaro @Laurie_Garrett @MackayIM I do think that due to the significant public threat, the regulatory considerations will be different compared to other vaccine/drugs. I foresee a similar situation as seen during the Ebola epidemic in 2015 when Merck/J&amp;J did their phase 1/2/3 studies more or less in parallel.
@ DavidSantoro1 @DrEricDing @HelenBranswell @drdianaro @Laurie_Garrett @MackayIM I do think That due to the significant public threat, the regulatory considerations will be different Compared to other vaccine / drugs. I foresee a similar situation as seen during the Ebola epidemic in 2015 When Merck / J & amp; J did Their phase 1/2/3 studies more or less in parallel.
Clinical Study Lead, Janssen Vaccines, J&J | Infectious Diseases, Virology and Vaccines | cycling, zwift and skiing | Tweets are my own
Clinical Study Lead, Janssen Vaccines, J & J | Infectious Diseases, Virology and Vaccines | cycling, skiing and zwift | Tweets are my own